chevron_leftBack
As of 14 June 2026, Tempest Therapeutics, Inc. has a market cap of $24.96M USD, ranking #35521 globally and #4879 in the United States.
It ranks #3203 in the Healthcare sector, and #1079 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$24.96MUSD
Enterprise Value
$24.32MUSD
EBITDA (TTM)
-$26.31MUSD
Net Income (TTM)
-$26.26MUSD
PB Ratio
1.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Matthew Angel
open_in_new
Employees
4
Founded
2011
Website
tempesttx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 3% | -5.1% | -2.9% | -40% | -85% | -79% |
News
Loading...
TPST Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
TPST
Tempest Therapeutics Inc
ISIN: US87978U2078
Shares Out.:
Shares Outstanding:
14.807M1
Shares Float:
8.389M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.74 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
3M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
2M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
1M%
|
97.4
|
|
NYSE: MRK
|
$274.03B
1M%
|
15.1
|
|
NYSE: PFE
|
$149.38B
598K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
471K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
1M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
1M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
1M%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
728K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
441K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
434K%
80.96B GBP
|
14.6
|
chevron_leftBack